Updated Dec 16, 2007 at 3:34 EST.
Sciele Pharma Inc.
is a pharmaceutical company dealing with specialty medicines.
They have teamed up with Solutions Holdings PLC ( Plethora Solutions ).
This is a specialty pharmaceutical company which develops products for the treatment and management of urological disorders.
The two companies announced recently that they have begun enrolling patients in the US, for the phase III clinical trials of PSD502.
This drug had been created for the treatment of premature ejaculation.
PSD502 is the mixture of two different marketed drugs.
One is lidocaine and the other is prilocaine.
It is applied by a metered dose of aerosol.
In multi-center phase II studies, the product has proven to treat premature ejaculation by increasing ejaculatory latency times when compared to a placebo.
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
